Tarsus Pharmaceuticals
Latest round
- Series B
Last raised
- Jan 2020
Total raised
- $60M
Investors
- 6
About Tarsus Pharmaceuticals
operates as a manufacturing company providing eye care therapeutics to treat patients with Demodex blepharitis. The firm's product is TP-03, a topical ophthalmic. In February 2024, Tarsus Pharmaceuticals, Inc.81 million shares at USD 32 per share on the Nasdaq Global Select Market under the ticker symbol "TARS". Tarsus Pharmaceuticals, Inc. has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of common stock as part of the listing. Tarsus Pharmaceuticals, Inc. developed a product known as XDEMVY, which is a treatment for Demodex blepharitis, an ocular disease caused by an infestation of Demodex mites. It helps to solve eyelid inflammation, redness, and irritation and for other eye-related conditions, including meibomian gland disease and rosacea, as well as Lyme disease prevention.
Who invested in Tarsus Pharmaceuticals
6 investors across 1 round
See all investors in Tarsus Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 8, 2020
Amount
$60M
Investors
Questions about Tarsus Pharmaceuticals
Who invested in Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tarsus Pharmaceuticals raised?
Tarsus Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Tarsus Pharmaceuticals last raise money?
Tarsus Pharmaceuticals's most recent round on record is a Series B, in Jan 2020.
What does Tarsus Pharmaceuticals do?
operates as a manufacturing company providing eye care therapeutics to treat patients with Demodex blepharitis.
Where is Tarsus Pharmaceuticals headquartered?
Tarsus Pharmaceuticals is headquartered in Irvine, US.
Which VCs invest in companies like Tarsus Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Tarsus Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Tarsus Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.